Bioptic

Bioptic Equity Growth

The Year-over-Year Equity Growth of Bioptic (6850.TWO) as of Oct 24, 2026 is 4.16 %. In the previous year, Year-over-Year Equity Growth was 3.17 % — a change of 31.05% (higher).

Equity Growth

4.16 %

YoY

31.05%

Last updated:

Year-over-Year Equity Growth of Bioptic is 2024 4.16 % . Year-over-Year Equity Growth of Bioptic was 2023 3.17 % . It decreases by 31.05% higher compared to the previous year.

The Bioptic Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2021
104.38 TWD
Jan 1, 2022
13.70 TWD
Jan 1, 2023
3.17 TWD
Jan 1, 2024
4.16 TWD
The Bioptic Equity Growth history
YEAREquity GrowthYoY
4.16 %+31.05%
3.17 %-76.84%
13.70 %-86.88%
104.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptic Stock analysis

What does Bioptic do? BiOptic Inc generates revenue through the sale of capillary electrophoresis instruments, including the Qsep100, Qsep1, and Qsep400 series, which are used for biomolecule separation and detection. The company also sells related consumables such as S1, S2, S3, F3 cassettes for DNA fragment analysis, R1 and NR1 cassettes for RNA detection, P2 cassettes for protein analysis, and Q series for quantitative detection. Additionally, BiOptic Inc offers reagents including polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection reagents, and food-related reagents. These products are primarily sold to customers in China, Hong Kong, and Taiwan, with the company focusing on the healthcare and research sectors. The firm's main customer segments include laboratories, hospitals, and research institutions that require advanced detection equipment and consumables for genetic and molecular analysis. BiOptic Inc's product portfolio targets both human and veterinary medical applications, as well as food safety testing, indicating a diversified market approach. The company's focus on high-precision instruments and specialized reagents positions it to serve clients needing reliable solutions for nucleic acid and protein analysis. BiOptic Inc's revenue streams are derived from direct sales of its instruments, cassettes, and reagents to end-users in the healthcare and research sectors. The company's products are designed for specific applications, such as DNA, RNA, and protein detection, which drives demand from specialized laboratories and medical facilities. By offering a comprehensive range of products, BiOptic Inc ensures that its customers can access all necessary tools for their molecular analysis needs within a single supplier. Bioptic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptic stock

Year-over-Year Equity Growth of Bioptic is 4.16 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Bioptic since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Bioptic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Bioptic

All Key Metrics — Bioptic